Feb 23 (Reuters) - Gilead Sciences said ⁠on ⁠Monday it will ⁠buy cancer therapy partner Arcellx for ​an implied equity value of $7.8 billion, expanding their cell ‌therapy development collaboration ...

A dual-action nanomaterial uses cancer’s own chemistry to destroy tumors while leaving healthy cells unharmed.

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Scientists in China have unveiled a breakthrough way to mass-produce powerful cancer-fighting immune cells in the lab. By ...

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

Johnson & Johnson, the healthcare and lifestyle giant announced a more than $1 billion dollar investment in next generation ...

UConn Center on Aging researchers have published a new editorial in the journal Aging titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?" In ...

The findings were published in the journal Cell. The research was led by Leonie Uhl, Amel Aziba, and Sinah Löbbert, working with colleagues from the University of Würzburg (JMU), Massachusetts ...

Can fragments of tumor DNA in the blood predict whether chemotherapy will be effective? Researchers at the Princess Máxima ...